skip to content
Primary navigation


Drug - Rezurock™ (belumosudil) [Kadmon Pharmaceuticals, LLC.]

April 2022

Therapeutic area - Immunosuppressives, Oral

Initial approval criteria

  • Patient is at least 12 years old AND
  • Patient has a diagnosis of chronic graft-versus-host disease (chronic GVHD) AND
  • Patient has failed at least two prior lines of systemic therapy AND
  • Rezurock is prescribed by or in consultation with a transplant specialist AND
  • Comprehensive review of the patient’s medication profile is conducted; and if applicable, interacting drugs are identified and dosage is adjusted accordingly AND
  • Patient of reproductive potential is advised of the potential risk to a fetus and to use effective contraception

Renewal criteria

  • Patient continues to meet initial approval criteria AND
  • Patient has not experienced disease progression AND
  • Patient has not experienced unacceptable adverse drug effects (e.g., severe nausea, severe vomiting, severe diarrhea, hepatotoxicity)

Quantity limits

  • 30 tablets per 30 days

Background information

Rezurock is a kinase inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.


MHCP Provider Resource Center 651-431-2700 or 800-366-5411

back to top